MPE webinar on personalised medicines in myeloma and AL amyloidosis
Myeloma Patients Europe (MPE) will hold a webinar on personalised medicines in myeloma and AL amyloidosis on Wednesday 6 May 2020 from 18:00 – 19:00 CET.
Watch the webinar on Minimal Residual Disease (MRD) in myeloma and related diseases held by MPE
Myeloma Patients Europe (MPE) held a webinar Minimal Residual Disease (MRD) in myeloma and related diseases given by Paula van Hennik, Committee for Medicinal Products for Human Use (CHMP) member at the European Medicine Agency (EMA).
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19
The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus).
MPE webinar on Minimal Residual Disease (MRD) in myeloma and related diseases
Myeloma Patients Europe (MPE) will hold a webinar on Minimal Residual Disease (MRD) in myeloma and related diseases on Monday 20 April 2020 from 18:00 – 19:00 CET.
COVID-19 treatment in myeloma patients
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have myeloma and other blood cancers.
Watch the webinar on big data, the Harmony example held by MPE
Myeloma Patients Europe (MPE) held a webinar on big data, the Harmony example given by Ana E. Rodríguez, Institute for Biomedical Research of Salamanca (IBSAL), Spain.
How to cope with confinement during the COVID-19 outbreak
The increase in the number of people affected by COVID-19 (coronavirus) has generated great concern, and has forced a number of countries to implement measures in order to stop the spreading of the virus. These measures are, in many countries, very restrictive and can include social distancing and working from home in a situation of self-quarantine or isolation, in order to avoid infection of self, and others.
Message from the president of Myeloma Patients Europe, Hans Scheurer on COVID-19
Whilst many people will only get mild to moderate symptoms of COVID-19 (coronavirus), myeloma and AL amyloidosis patients should be extra cautious during the current outbreak. The president of Myeloma Patients Europe (MPE), Hans Scheurer, sends a message to MPE members, myeloma and AL amyloidosis patients. Watch it below:
Job offer – Patient Advocacy Programme Manager
We are seeking a Patient Advocacy Programme Manager to join our growing team!